Santen eyes uveitis market with top-line sirolimus data

Japanese eye company Santen has released positive top-line data for the first Phase III trial of its sirolimus-based uveitis treatment.

Japanese eye company Santen has released positive top-line data for the first Phase III trial of its sirolimus-based uveitis treatment.

The trial, dubbed SAKURA Study 1, is evaluating intravitreal injections of sirolimus at three doses in 347 patients with non-infectious...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Musculoskeletal

More from Therapeutic Category